A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study but more bladder and breast cancers have been found in patients treated with the drug.
"In all studies so far completed, 1.4 percent of patients treated with dapagliflozin developed some type of cancer, compared with 1.3 percent of control group patients, said Elisabeth Bjork, vice president of development for dapagliflozin at AstraZeneca.
Nine bladder cancers have been observed in 5,478 patients treated with the experimental drug, compared with one bladder cancer seen in the 3,156 patients in control groups.
Six of the 10 had blood in the urine, known as hematuria, when they entered trials and five were diagnosed within a year after their study started.
The companies also said nine cases of breast cancer have occurred in 2,223 women on dapagliflozin and one has been observed out of 1,053 women in control groups. All were diagnosed within a year after studies started."
----
Irony
Patients who became diabetic after taking the antipsychotic Abilify or Seroquel ironically could end up with breast or bladder cancer from the company duo's created diabetes drug dapagliflozin. Talk about a negative twist of fate.
"Bristol and AstraZeneca filed earlier this year for U.S. and European regulatory approval of dapagliflozin. An advisory committee to the U.S. Food and Drug Administration is set to review the application on July 19."
Does the risk outweigh the benefit?
Posts
0 comments:
Post a Comment